Efficacy and safety of different chemotherapy regimens concurrent with radiotherapy in the treatment of locally advanced cervical cancer

医学 顺铂 内科学 宫颈癌 紫杉醇 放化疗 外科肿瘤学 化疗 肿瘤科 放射治疗 不利影响 临床终点 癌症 随机对照试验
作者
Yaping Wu,Peng Jiang,Zhiying Chen,Wei Li,Bin Dong,Yongchun Zhang
出处
期刊:BMC Cancer [BioMed Central]
卷期号:24 (1) 被引量:1
标识
DOI:10.1186/s12885-024-12358-8
摘要

Abstract Background Evaluate the efficacy and safety of different chemotherapy regimens concurrent with radiotherapy in treating locally advanced cervical cancer (LACC). Methods Retrospective data was collected from LACC patients who were treated at our institution. These patients were categorized into three groups: the single-agent cisplatin (DDP) chemoradiotherapy group, the paclitaxel plus cisplatin (TP) chemoradiotherapy group, and the nanoparticle albumin-bound (nab-) paclitaxel combined with cisplatin (nPP) chemoradiotherapy group. The primary endpoints were overall survival (OS) and progression-free survival (PFS) and the secondary endpoints were objective response rate (ORR) and incidence of adverse events (AEs). Results A total of 124 patients were enrolled (32 in the DDP group, 41 in the TP group, and 51 in the nPP group). There were differences in OS ( P = 0.041, HR 0.527, 95% CI 0.314–0.884) and PFS ( P = 0.003, HR 0.517, 95% CI 0.343–0.779) between the three groups. Notably, the 2-year OS rate was significantly higher in the nPP group compared to the DDP group (92.2% vs. 85.4%, P = 0.012). The 2-year PFS rates showed a marked increase in the TP group (78.0% vs. 59.4%, P = 0.048) and the nPP group (88.2% vs. 59.4%, P = 0.001) relative to the DPP group, with multiple comparisons indicating that the 2-year PFS rate was significantly superior in the nPP group versus the DDP group (88.2% vs. 59.4%, P = 0.001). Moreover, the ORR was also significantly higher in the nPP group than in the DDP group ( P = 0.013); and no statistically significant differences were found in the incidence of AEs among the groups ( P > 0.05). Conclusions In LACC treatment, the two cisplatin-based doublet chemotherapy regimens are associated with better outcomes, with the nab-paclitaxel plus cisplatin regimen showing better efficacy than the paclitaxel plus cisplatin regimen. Furthermore, the AEs associated with these regimens were deemed tolerable. These findings could provide a reference for the clinical treatment of LACC. However, further prospective studies are needed to verify it.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
留胡子的思真完成签到,获得积分10
2秒前
2秒前
假发君完成签到,获得积分10
2秒前
chenchen发布了新的文献求助10
3秒前
3秒前
孔嘉宁关注了科研通微信公众号
4秒前
斯文败类应助热情的果汁采纳,获得30
5秒前
卷卷完成签到,获得积分10
5秒前
DI完成签到,获得积分10
5秒前
5秒前
小二郎应助飞天意面采纳,获得10
5秒前
wu发布了新的文献求助10
6秒前
忧郁含海完成签到,获得积分10
6秒前
mm发布了新的文献求助10
6秒前
Michael发布了新的文献求助10
7秒前
郭菱香完成签到 ,获得积分10
7秒前
bkagyin应助zjl900111采纳,获得10
8秒前
从容的小虾米完成签到,获得积分10
8秒前
希望天下0贩的0应助chun采纳,获得10
8秒前
聪慧小霜应助清秀送终采纳,获得10
8秒前
9秒前
9秒前
Vicki完成签到,获得积分10
9秒前
wxs完成签到,获得积分10
10秒前
leezhen完成签到,获得积分10
10秒前
上官若男应助Michael采纳,获得10
10秒前
喵喵发布了新的文献求助10
10秒前
Blue完成签到,获得积分10
10秒前
bpg28发布了新的文献求助10
11秒前
eeo完成签到,获得积分10
11秒前
Orange应助沟通亿心采纳,获得10
11秒前
阿猫发布了新的文献求助10
12秒前
12秒前
12秒前
wxs发布了新的文献求助10
13秒前
13秒前
CodeCraft应助铁柱采纳,获得10
13秒前
博士后完成签到,获得积分10
13秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3970287
求助须知:如何正确求助?哪些是违规求助? 3515034
关于积分的说明 11176923
捐赠科研通 3250301
什么是DOI,文献DOI怎么找? 1795244
邀请新用户注册赠送积分活动 875732
科研通“疑难数据库(出版商)”最低求助积分说明 805039